Rapidly progressive Epstein-Barr virus-associated lymphoproliferative disorder unpredictable by weekly viral load monitoring

Internal Medicine

Volumn 49, Issue 10, 2010, Pages 931-935

  Wakabayashi, Shihoko ^a,b   Ohashi, Kazuteru ^a   Hanajiri, Ryo ^a   Kobayashi, Takeshi ^a   Yamashita, Takuya ^a   Akiyama, Hideki ^a   Sakamaki, Hisashi ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Anti thymocyte globulin; Aplastic anemia; Epstein barr virus associated lymphoproliferative disorders; Rituximab; Unrelated bone marrow transplantation

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; RITUXIMAB; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ANEMIA; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CONJUNCTIVA DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; EPSTEIN BARR VIRUS; FEVER; HEMATOMA; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MALE; MOUTH DISEASE; SINGLE DRUG DOSE; VIRUS LOAD; VIRUS REACTIVATION;

ANEMIA, APLASTIC; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; BONE MARROW TRANSPLANTATION; DISEASE PROGRESSION; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; YOUNG ADULT;

EID: 77952928085     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3114     Document Type: Article

References (14)

1. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94: 2208-2216, 1999.
2. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 35: 225-231, 2005.
3. Cohen J, Gandhi M, Naik P, et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 129: 229-239, 2005.
4. Ocheni S, Kroeger N, Zabelina T, et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 42: 181-186, 2008.
5. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV- lymphoproliferative disease following T-cell-depleted SCT. Blood 98: 972-978, 2001.
6. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99: 4364-4369, 2002.
7. Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 37: 539-546, 2006.
8. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 95: 1502-1505, 2000.
9. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B- lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 11 (Suppl 1): 113-116, 2000.
10. Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Hae-matol 115: 112-118, 2001.
11. Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108: 2874-2880, 2006.
12. Meijer E, Cornelissen JJ. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol 15: 576-585, 2008.
13. Ahmad I, Cau NV, Kwan J, et al. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell trans-plantation. Transplantation 87: 1240-1245, 2009.
14. Faraci M, Caviglia I, Morreale G, et al. Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children. In: Bone Marrow Transplantation Advance Online Publication. 26October 2009; doi:10.1038/ bmt.2009.302.